S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

LaserAway Marks Two Decades of Growth with 232nd Clinic Opening

Lubbock, Texas, now hosts the 232nd location for LaserAway, a milestone that coincides with the aesthetics brand's twentieth anniversary. Since its 2006 launch in West Hollywood, the company has expanded across 36 states, maintaining a strictly corporate-owned model that avoids the fragmentation typically found in retail dermatology chains.

LaserAway Marks Two Decades of Growth with 232nd Clinic Opening
Photo: Bio & News

The new clinic at 4210 82nd St. continues the expansion strategy established by founders Dr. Roy Winston and brothers Scott, Brock, and Todd Heckmann. Over the past twenty years, the company has avoided a single clinic closure, a performance metric that sets it apart in the medical aesthetics sector. CEO Scott Heckmann attributes this longevity to the initial premise of democratizing high-end dermatological treatments, moving them from exclusive boutique settings into more accessible, standardized environments.

Operations at the Lubbock site, as with all company locations, rely on a clinical staff of nurse practitioners, physician assistants, and registered nurses. Oversight is provided by a medical board of more than 25 board-certified dermatologists, directed by Chief Medical Officer Dr. Will Kirby. The clinic will offer the brand’s standard suite of services, ranging from laser hair removal and injectables like Botox to body contouring procedures including CoolSculpting and Thermage.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!